Anavex Life Sciences Corp (AVXL)

[falconer66a]

An insomnia backdoor for blarcamesine against Alzheimer’s?

Wouldn’t this be curious, where sooner or later (well, later) blarcamesine is tested in a big double-blind clinical trial to gain regulatory authorization to sell and use blarcamesine to treat just the insomnia of Alzheimer’s? The new patent suggests this could be possible.

In that case, the only thing that needs to be shown (in the clinical trial) is that blarcamesine moderates or even eliminates the insomnia problems associated with Alzheimer’s disease. All of the other progressing symptoms of the disease would be unaddressed and play no part in the drug’s therapeutic use approval. Sleep, only, would need to be improved. Big Pharma could continue its Holy Grail quest for a drug that treats beta-amyloids, tau tangles, etc.

Of course, after a few months of thousands of Alzheimer’s patients getting restful blarcamesine sleep, it will be astonishingly noted that other disease symptoms have begun to abate. “Getting good sleep really helps Alzheimer’s patients” it will be proclaimed.

Of course, the patients will have to continue with their daily blarcamesine pills; otherwise, the Alzheimer’s would “return.”

The amyloid causation motif would continue unabated. But blarcamesine for Alzheimer’s insomnia would become the standard of care. Who’da thought?